Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

NeoTract Designates Dr. Greg Griewe as UroLift® Center of Excellence


News Image

“We are proud to name Dr. Greg Griewe as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Greg Griewe, MD, Pinehurst Surgical in Pinehurst NC, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Griewe has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are proud to name Dr. Greg Griewe as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “The UroLift System is a safe and effective treatment that allows physicians to treat men in-office under local anesthesia, so they can experience lasting symptom relief within days after receiving treatment.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Pivot Point Consulting Announces Advisory Board to Drive Growth Strategy


Pivot Point Consulting’s Advisory Board Members Daniel Herman and Mike Sweeney

We’re grateful to have such experienced senior healthcare IT leaders at the table with us and look forward to growing our team of advisory board members to bring in other capabilities aligned with our services to shape what we’re doing today, as well as our future.

Healthcare IT consulting leader, Pivot Point Consulting, a Vaco Company, announces a new Advisory Board to help shape and guide its growth strategy with the leadership team.

Comprised of CEOs and senior leaders of leading healthcare IT organizations, the Advisory Board will work with the leadership team to monitor trends shaping the industry and ensure market relevance and innovation given the changing healthcare ecosystem, as well as identify both strategic resources and acquisition opportunities.

The Advisory Board includes:

Daniel S. Herman, Founder of Aspen Advisors and former Managing Director of Informatics and Technology at The Chartis Group

Daniel founded and served as Managing Director of Aspen Advisors, an industry recognized information technology and operations improvement consulting firm comprised of over 130 professionals which merged with The Chartis Group in 2014. He also served as Senior Vice President in a privately held consulting firm (Dearborn Advisors, LLC), a Regional Vice President in a publicly traded healthcare information technology services firm (First Consulting Group), a manager in the healthcare consulting practice of a national CPA firm (KPMG) and an implementation manager for a healthcare software vendor (McKesson).

For more than 30 years, Daniel advised leading academic medical centers, integrated delivery networks, physician group practices, specialty providers and provider-sponsored managed care organizations on enhancing the value of their information technology investments. An early advocate for improving care delivery and operations through the effective use of technology, he is a Life Fellow of the Healthcare Information Management & Systems Society (HIMSS), served on the Board and as a past president in the Colorado, Greater Chicago and Western Pennsylvania HIMSS Chapters and has authored numerous articles and presentations on leadership, various aspects of Healthcare Information Technology Management and obtaining value from IT investments.

Mike Sweeney, former President and CEO of MaxIT Healthcare

Mike was the President and CEO of MaxIT Healthcare, which was acquired by Science Applications International Corporation (SAIC). MaxIT employed over 1,000 consultants and specialized in the implementation and optimization of electronic health record (EHR) systems from major software vendors for healthcare organizations across North America. He also served in senior executive positions at McKesson and at Esurg, a healthcare e-commerce business. Mike brings deep experience developing and delivering a range of healthcare IT services and solutions primarily to commercial hospital groups and other medical delivery organizations. He retired after the acquisition and now serves as a Board Director and Advisor to several companies.

“The Advisory Board illustrates Pivot Point Consulting’s commitment to exceptional quality and sustained growth. We’re grateful to have such experienced senior healthcare IT leaders at the table with us and look forward to growing our team of advisory board members to bring in other capabilities aligned with our services to shape what we’re doing today, as well as our future,” said Rachel Marano, Managing Partner.

About Pivot Point Consulting

Pivot Point Consulting enables healthcare organizations to realize the most value from their technology and data through their KLAS ranked advisory, implementation/optimization, managed services and talent solutions.

The company provides strategy and consulting services for providers, payers and life sciences organizations – with 450 employees serving 85+ clients across the United States. Pivot Point Consulting has earned many industry and workplace quality awards including: Top three Best in KLAS for HIT Implementation and Support for four years running (2015, 2016, 2017 and 2018), Highest Rated Vendor in KLAS Implementation Services in the Select Category (July 2017), #1 in KLAS for Epic Consulting in the Select Category (2016), #9 in Modern Healthcare’s Best Places to Work in 2016.

For more information about Pivot Point Consulting, visit https://pivotpointconsulting.com/. Follow us on LinkedIn.

Share article on social media or email:

Myant to showcase line-up of heart health management apparel and textiles at CES 2020 to democratize access to electrocardiography for people across society


News Image

Scaling access to medical diagnostics will be necessary to improve global health – novel tools and technologies like wearable textiles holds the potential value to democratize healthcare in a way that has never previously been imagined.

Myant Inc., the pioneers in Textile Computing™, will be showcasing a line-up of textile products that enable continuous and ambient heart health management at CES 2020 (January 7-10, Las Vegas), including apparel from the Skiin Connected Health & Wellness line which was honored as a winner in the Health & Wellness category of the CES 2020 Innovation Awards.

While electrocardiography, or the study of the electrical activity of the heart, has long been recognized as a crucial diagnostic modality in the management of overall health, access to cardiac diagnostics has long been restricted within the context of clinical settings, and offered only to those suffering from, or at significant risk of cardiac disease. Factors such as high cost of care and complexity in diagnostic devices have led to an approach towards heart health management that is largely reactive in nature as opposed to truly preventative.

Enabling Access to Heart Health Management for All via Everyday Clothing

Heart disease is still the leading cause of death in the world, and there is no current way to monitor the heart in an ambient, passive, seamless, and reliable manner – essential to preventative care. Myant’s mission is to create that connection to the human body, through everyday products that are already pervasive in our lives and continuously being used, in order to connect everyone, regardless of their age, gender or ability, and throughout all facets of their lives (i.e. sleep, work, play/fitness, etc.).

Leading healthcare experts like Dr. Suraj Kapa, a cardiologist and medical innovation expert from the Mayo Clinic who advises on healthcare strategy for Myant, agree on the potential for textile to transform the way care is delivered and managed. “Scaling access to medical diagnostics will be necessary to improve global health – novel tools and technologies like wearable textiles holds the potential value to democratize healthcare in a way that has never previously been imagined,” noted Dr. Kapa.

Myant has been working to develop textiles that can sense the electrical activity of the heart, and deploying these textiles in different form factors (i.e. clothing, furniture, car seats, etc.). By distributing the data captured by these interfaces through a cloud-based, AI-enabled platform, Myant is ushering in a model for heart health management that is continuous, ambient, preventative, and democratized. This will create continuous access to best-in-class heart health machine learning algorithms, something that is currently confined to leading hospitals and cardiologists.

Myant will be bringing these products to market under its connected brand Skiin. The line-up of apparel can record ECG data from multiple points of the body to obtain different ECG vectors resulting in more accurate and continuous heart monitoring. The Skiin line-up of interfaces to be showcased at CES 2020 includes:

Interface Details

Underwear    

  • 2-lead electrocardiogram (ECG)
  • Includes activity and temperature monitoring, plus more
  • Launching in Q1 2020

Bra    

  • 3-lead ECG recording garment
  • Includes activity and temperature monitoring, plus more
  • Launching in Q1 2020

Undershirt    

  • 3 to 5-Lead ECG shirt with multiplexing capability between electrodes
  • Includes activity and temperature monitoring, plus more
  • Launching in Q2 2020

Polo Shirt    

  • Single-lead ECG recording polo shirt
  • PPG sensor for ECG-PPG cuffless blood pressure measurement
  • Launching in Q4 2020

Baby Onesie    

  • 3 to 5-lead ECG onesie with multiplexing capability between electrodes
  • Includes activity, position and temperature monitoring, plus more
  • Launching in Q4 2020

Pregnancy Band    

  • 12-lead maternal ECG and fetal ECG monitoring abdominal band
  • Lead selection capability from 16 electrodes for optimal fetal ECG recording

12-Lead Holter Monitor    

  • 12-lead medical grade cardiac Holter monitor
  • Utilizing Myant proprietary fully textile dry motion-resistant active electrodes
  • ECG recording with continuous mechanical/electrical electrode contact monitoring
  • Devices are under pre-submission process with the FDA and are not currently for sale under any jurisdiction.

Distributing ECG and Other Biometric Insights via Social Connectedness App, Deepening Connection with Circle of Care to Address the Social Determinants of Health:

Human interaction and social connectedness are fundamental human needs, and an individual’s health and wellbeing are known to be intrinsically connected to these social determinants. While people in the past lived in tighter knit communities and thus were able to stay more connected and better care for each other, our social connections in the modern world are less physically connected and more dispersed. Myant’s mission is to use technology to help alleviate this problem, and connect people to themselves, their communities, AI and the world around them.

In light of this, ECG data and other biometric data gathered by Skiin garments will be distributed via the Skiin app (powered by the Myant Platform) which promotes sharing of information between the user and their Care Circle. The aim of the app experience is to create a continuous, ambient, and more meaningful bond between the user and their caregivers (e.g. loved ones, healthcare professionals, etc.), providing the user with the support they need to achieve better health outcomes. Members of the Care Circle can check-in on the user via the app to understand their physical and emotional state at a glance, providing greater peace of mind. AI on the Myant Platform works with a nudge system build into the app to alert the user and their Care Circle of important changes to the user’s state, suggesting meaningful actions to help improve wellbeing. The end result is the redistribution of care, from isolated episodes in clinical contexts to a continuous, distributed community-based model in which the user, their loved ones, healthcare providers, and AI all work together to promote better outcomes.

Myant at CES 2020

The democratization of heart health management through connected textiles is just one of the many possibilities enabled by the Myant Platform, which provides a continuous, ambient and passive connection between people and their bodies, their communities, and their environments across all aspects of daily life (i.e. home, work, and play). Myant’s presence at CES 2020 was designed to encourage others to envision these possibilities, inspiring the world to challenge the way they see everyday textile and to reimagine the value that these objects can provide. Myant invites you to visit their booth at CES 2020 (Booth #43925, Sands Expo, Health & Wellness) to discover more about a world connected by textiles.

For more information or to schedule a meeting with Myant at CES 2020, please contact:

Brian Fung

Marketing Strategist at Myant

brian.fung@myant.ca, 416-423-7906 x401

Frank Florio

VP, Strategy & Business Development at Myant

frank.florio@myant.ca, 416-423-7906 x421

About Myant Inc.

Myant has created the world’s first platform that continuously and ambiently connects people to their bodies, to each other, and to the world around them. Using connected textiles that can sense and react to the human body and a platform that enables machine learning driven health and performance outcomes, Myant is on a mission to transform human connectedness. With an extensive patent portfolio, key exclusive relationships within the textile computing industry, a multidisciplinary team of researchers, engineers, data scientists, fashion designers and knitting specialists, and over 80,000 ft² of manufacturing capacity, Myant is changing the way people across society connect. Connect with us to find out how we can help you create innovative solutions powered by connected textiles and the Myant Platform. Visit https://www.myant.ca to learn more.

MemoryCare.com Names the Best Facilities for Senior Memory Care in Huntsville, AL


News Image

MemoryCare.com, a comprehensive resource for caregivers and older adults living with memory impairment, has announced the Best Memory Care Facilities in Huntsville, Alabama. The guide identifies 5 memory care communities based on location, access to experts, facility features and amenities.

According to the Alzheimer’s Association, 5.6 million people age 65 and older are living with Alzheimer’s dementia. In Huntsville, the number of senior deaths related to Alzheimer’s increased by 30 percent between 2013 and 2017. Memory care facilities offer activities and therapies to help delay or halt cognitive decline. They also give family members and caregivers peace of mind by providing a safe environment for loved ones.

“There’s a high demand for quality memory care all across our nation; specifically, in cities like Huntsville, which experienced a rapid increase in Alzheimer’s related deaths,” says Joyce Collins. “MemoryCare.com provides free resources to help families find the best facilities.”

Through hours of research and an intensive selection process, MemoryCare.com was designed to help caregivers find effective solutions for their loved ones. The website not only highlights the best facilities in the city, it also shares information about cost, reviews from residents, type of care offered and more. For a detailed listing of the Best Memory Care Facilities in Huntsville, AL, please visit https://www.memorycare.com/huntsville-al-facilities/

2020 Best Memory Care Facilities in Huntsville, AL (in alphabetical order)

Brookdale Hampton Cove

Phone: (256) 248-9939

Address: 6379 Highway 431 S., Hampton Cove, AL 35763

Web: brookdale.com/hampton-cover

HarborChase of Huntsville

Phone: (256) 937-1018

Address: 4801 Whitesport Cir. SW., Huntsville, AL 35801

Web: harborchase.com/huntsville

Redstone Village

Phone: (800) 724-5535

Address: 12000 Turnmeyer Dr., Huntsville, AL 35803

Web: redstonevillage.org

Regency Retirement Village of Huntsville

Phone: (256) 852-0033

Address: 2004 Max Luther Dr., Huntsville, AL 35810

Web: regencyhuntsville.com

Thrive at Jones Farm

Phone: (256) 429-3008

Address: 2238 Cecil Ashburn Dr. SE, Huntsville, AL 38502

Web: thrivesl.com/jonesfarm

ABOUT MEMORYCARE.COM

MemoryCare.com provides tools and resources to help adults living with memory impairment and their families. The online guide uses data-driven research and expert evaluations to identify the best facilities across the nation. The MemoryCare.com team includes medical and elder care professionals as well as board of directors. For more information, visit https://www.memorycare.com/.

Share article on social media or email:

FDAnews Announces — China’s NMPA (CFDA):Latest Regulatory Updates with QMS-PMS Focus Webinar January 21, 2020


WCG FDANews

WCG FDANews

China’s NMPA (CFDA):

Latest Regulatory Updates with QMS-PMS Focus

An FDAnews Webinar

Tuesday, Jan. 21, 2020, 11:00 a.m.-12:30 p.m. EST

https://www.fdanews.com/chinanpma

China is the second-largest medical device and in vitro diagnostic (IVD) industry market globally. It is the only market with a 20 percent annual growth rate year after year.

Stay up to speed on the hundreds of new regulations introduced by China’s National Medical Products Administration (NMPA) — formally known as the China Food and Drug Administration.

What are the strategic factors to consider during the reform before submission?

Join us on Jan. 21 and get up to speed on the regulatory reform in China that impacts the medical device and IVD industry.

During the webinar, attendees will:


  • Determine how to leverage a legal agent in China to increase compliance by understanding their roles and responsibilities
  • Discover how to assess and determine the new piloted MAH system by understanding its MAH qualification requirements and responsibilities
  • Familiarize oneself with how to leverage overseas QMS for China operations by understanding China GMP regulations and Chinese culture differences
  • Find out how to comply with required adverse events (AE) and serious adverse events (SAE) reports, including how to differentiate between AE and SAE and when to report

Join us for clarity on China’s regulatory reforms impacting the medical device and IVD industry.

Interested in registering multiple sites?

Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally

to learn about our special multisite discount.

Webinar Details:

China’s NMPA (CFDA):

Latest Regulatory Updates with QMS-PMS Focus

An FDAnews Webinar

Tuesday, Jan. 21, 2020, 11:00 a.m.-12:30 p.m. EST

https://www.fdanews.com/chinanpma

Tuition:

$287 per site

Easy Ways to Register:

Online: https://www.fdanews.com/chinanpma

By phone: 888-838-5578 or 703-538-7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations.

Share article on social media or email:

MMJ International Holdings Overcomes Big Federal Deterrents In It’s Marijuana Drug Development Strategy


News Image

MMJ DEA MEETING

Duane Boise stated, “The FDA has made an award for ″Orphan Drug Designation″ for MMJ’s THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease”.

MMJ International Holdings, the premier medical cannabis research company, recently announced that the FDA has made an award for ″Orphan Drug Designation″ for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease. The drug, MMJ-002 is one of MMJ’s lead drugs and the company is confident that it will bring much needed relief to patients suffering from the debilitating effects of Huntington’s Disease.

Since 2015, MMJ has been advancing the science of medical marijuana federally legal through development of patient clinical trials and research. This latest award of Orphan Drug Designation is in keeping with MMJ’s mission to do everything possible to improve the lives of patients.

Francis Collins, director of the National Institutes of Health (NIH), recently interviewed on CSPAN, was discussing some of his concerns on marijuana and the lack of research. He mentioned that products must come from a single source and be consistent in clinical trials. Collins stated “When it comes to Cannabis the United States is at an interesting place. In order to use federal funds to research the plant and its compounds, the products must come from a single source: a government-authorized farm at the University of Mississippi that cultivates marijuana.

However, MMJ International Holdings has accomplished a major milestone with the DEA’s recent approval of MMJ International Holdings, THC and CBD international shipment to the United States for Multiple Sclerosis, Huntington’s Disease Drug Development. MMJ has established a leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.

Director Francis Collins also stated, “It’s going to be very hard to interpret data about smoked marijuana when the actual nature of the product is vastly different depending on where you got it with respect to properties like THC and CBD content. We’d really like to have studies where you’re studying those compounds in pure form so you can see what they’re doing,” he said. “But again because of various limitations of Schedule I limits, we are not able to do as much as we would like.”

MMJ International Holdings, having overcome this logistical hurdle, has provided for the production of proprietary cannabis-based gel capsules to help treat those with Huntington’s Disease or Multiple Sclerosis. A new product mix of THC (tetrahydrocannabinol) and CBD (cannabidiol) will comply with the harsh guidelines set by the U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA). With MMJ following these guidelines set by the FDA and DEA we can ensure our product is consistent and meets all standards to make it an effective drug for patients who suffer from these debilitating diseases.

MMJ International Holdings already has several academic institutions preparing to study cannabis in Multiple Sclerosis and Huntington’s disease. “MMJ clinical trials will provide the necessary data to prove that cannabis can treat essential tremors, a neurological disorder that causes involuntary shaking.” Tim Moynahan the company chairman further stated that, “Ultimately, there’s so much interest in THC and CBD as a treatment modality, so MMJ will be providing the clinical research data necessary to prove patient dosing, safety, and efficacy.”

“Approval by DEA and FDA trials is another “big deterrent” to research is the extensive series of hurdles that scientists must overcome to receive approval to study marijuana”, Collins said. Researchers must be cleared by the Drug Enforcement Administration (DEA) and also submit an investigational new drug application to the Food and Drug Administration in order to conduct cannabis-involved clinical studies on humans.

“MMJ International Holdings has submitted to the FDA an Investigational New Drug application” stated Duane Boise, CEO. “We are pleased with the FDA ‘s cooperation and support to facilitate our company mission to service the unmet needs of patients suffering from MS and Huntington’s disease.”

“As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”

In conclusion, MMJ International Holdings has established a leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise. MMJ is successfully developing several prescription medications derived from the cannabis plant for the treatment of spasticity and chorea due to multiple sclerosis and Huntington’s disease.

The company has a pipeline of additional clinical stage cannabinoid and other natural botanical product candidates for both orphan and non-orphan indications with a specific focus on neurological conditions.

Share article on social media or email:

Envision Dallas Unveiled as New Name of Dallas Lighthouse for the Blind


Logo

Dallas Lighthouse for the Blind has been renamed Envision Dallas and officially become an entity of Wichita, Kan.-based Envision, Inc.

We are proud to expand our geographic footprint and mission into the Dallas area to meet a growing need for low vision rehabilitation, programs, services and employment.

Envision today announced Envision Dallas as the new name for Dallas Lighthouse for the Blind. The rebranding formalizes a relationship initiated in 2018, when the Wichita, Kansas-based Envision added Dallas Lighthouse for the Blind to its growing family. With locations in 11 states, Envision is one of the country’s largest employers of people with visual impairments. Envision’s mission is to improve the quality of life and provide inspiration and opportunity for people who are blind or visually impaired through employment, outreach, rehabilitation, education and research.

“We are proud to expand our geographic footprint and mission into the Dallas area to meet a growing need for low vision rehabilitation, programs, services and employment,” said Michael Monteferrante, president and CEO of Envision. “We look forward to the evolution of Envision Dallas into an even more robust organization led by Executive Director David Stupay and to identifying additional opportunities to help people with vision loss nationwide.”

Stupay, a veteran leader of multiple agencies in several states that help children and adults with developmental disabilities, was named as the new executive director on December 12.

Established in 1931, Envision Dallas currently serves 150,000 people in 11 North Texas counties who are blind or low vision. Since joining the Envision family, Envision Dallas has served an increasing number of people with vision loss through new initiatives and strategic leadership. In October, Envision Dallas announced it will become the new home of the American Foundation for the Blind Center on Vision Loss and Esther’s Place, a specially designed model apartment that helps individuals who are blind or low vision learn to live more independently.

About Envision: Envision promotes advocacy and independence for those who are blind or low vision. Founded in 1933, Envision is one of the largest employers of individuals with vision loss in the nation. Headquartered in Wichita, Kan., Envision’s mission is to improve the quality of life and provide inspiration and opportunity for people who are blind or visually impaired through employment, outreach, rehabilitation, education and research. For more information, visit http://www.envisionus.com.

Share article on social media or email:

Catalent Completes Purchase of Biologics Fill-Finish and Oral Solid Dose Facility in Anagni, Italy


The Anagni facility supplements our European commercial supply capabilities and will integrate well with our existing global early development and clinical supply sites to smooth the transition from development to commercial supply.

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced the completion of the purchase of Bristol-Myers Squibb’s biologics, sterile, and oral solid dose product manufacturing and packaging facility in Anagni, Italy.

The 28,000 square-meter (305,000 square-feet) facility has a demonstrated track record in technical transfers and successful commercial product launches. It offers extensive capabilities in aseptic liquid and powder filling for biologics and sterile products across multiple vial sizes, and comprehensive primary and secondary packaging solutions, including serialization, to support product launches for oral solids, sterile, and biologics products. Catalent has also announced that it plans to make further investments in the site’s growth.

“The Anagni facility supplements our European commercial supply capabilities and will integrate well with our existing global early development and clinical supply sites to smooth the transition from development to commercial supply,” commented Alessandro Maselli, Catalent’s President and Chief Operating Officer. “Anagni provides our European customers with great biologics and oral dose capabilities that can help us reduce time-to-market, simplify tech transfers, and minimize program risk.”

As part of the acquisition, Catalent will continue to manufacture the existing Bristol-Myers Squibb product portfolio currently produced at the site.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

Sleep Studies Used To Diagnose Sleep Apnea Assessed on “Behind The Scenes” With Laurence Fishburne


News Image

In the new episode of “Behind The Scenes,” the show will interview sleep apnea experts about the tests utilized in the detection of the disease.

Award-winning actor Laurence Fishburne has taken on many parts throughout the years but is also involved in educational television. In an upcoming episode of of Behind The Scenes Laurence Fishburne will introduce new content on sleep studies taking place to diagnose sleep apnea. The show is of the informational variety and reviews a broad spectrum of issues influencing people all over the globe.

It is estimated 22 million Americans suffer from moderate to severe sleep apnea. Roughly 26% of adults between the ages of 30-70 may have the sleep disorder. Sleep apnea makes a person repeatedly stop and begin breathing while asleep. The disease increases the risk of heart disease, high blood pressure, depression, stroke, and Type 2 diabetes.

Medical experts are conducting studies to detect the disease to treat it properly. The studies include nocturnal polysomnography and home tests. Nocturnal polysomnography tests monitor the heart, brain and lung activity, leg and arm movements, breathing patterns, and blood oxygen levels while hooked up to a machine during sleep. Home tests measure the blood oxygen level, breathing and airflow patterns, and heart rate.

In the new episode of “Behind The Scenes,” the show will interview sleep apnea experts about the tests utilized in the detection of the disease. They will also discuss how sleep apnea is impacting people worldwide.

The educational program “Behind The Scenes” with Laurence Fishburne is given a careful review before broadcast to a public audience. As an acknowledgment for its efforts, the show has received a multitude of awards.

Share article on social media or email:

Bright Now!® Dental in Mesa, AZ to Host a Free Dental Clinic


News Image

Bright Now! Dental Team

In partnership with the Smiles for Everyone Foundation, Bright Now!® Dental will provide free dental services for low-income, underinsured individuals at its Mesa, Arizona office on February 16th.

Dental services provided include same-day procedures such as exams and x-rays, fillings, cleanings and extractions. For more information, please visit the Bright Now! Dental website.

About Bright Now!® Dental

Bright Now! ® Dental provides general dentistry, children’s dentistry and, in select locations, specialty care services such as orthodontics, oral surgery, periodontics and endodontics at over 150 offices across Arizona, California, Colorado, Florida, Indiana, Maryland, Ohio, Oregon, Pennsylvania, Utah, Virginia and Washington. Bright Now! Dental’s Mesa office is operated by Modern Dental Professionals – Arizona, Inc., P.C. (the “Group”). The Group is affiliated with Smile Brands Inc., one of the largest providers of business support services to dental groups in the United States. Smile Brands Inc. provides comprehensive business support services through exclusive long-term service agreements with affiliated dental groups, so dentists can spend more time caring for their patients and less time on the administrative, marketing and financial aspects of operating a dental practice. Smile Brands is a portfolio company of Gryphon Investors (“Gryphon”), a leading middle-market private equity firm based in San Francisco, CA. For more information, visit http://www.smilebrands.com.

About the Smiles For Everyone Foundation

The Smiles for Everyone Foundation is a 501(c)(3) nonprofit organization with the mission of delivering smiles for everyone by providing free dental care for those in need, both at home in the U.S. and around the world. Since 2011, the Smiles for Everyone Foundation has delivered over 24,000 smiles and $18 million in donated dentistry. The foundation currently supports programs which provide free dental care to those in need in Cambodia, Ghana, Laos, Nicaragua, Paraguay, Thailand, and the United States. For more information or to make a donation, visit http://www.smilesforeveryone.org.

Contacts:

Bright Now!® Dental                    

Jody Martin    

PR@smilebrands.com                            

714.427.1299                    

Smiles for Everyone Foundation

Crystal Strait

crystal.strait@smilesforeveryone.org

714.824.5037

Share article on social media or email: